Curative Biotechnology, Inc. (CUBT)
USD 0.01
(5.93%)
USD 0.01
(5.93%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.83 Million USD | -41.4% |
| 2022 | 4.43 Million USD | -11.24% |
| 2021 | 4.99 Million USD | 8.55% |
| 2020 | 4.6 Million USD | 84354.28% |
| 2019 | 5451.00 USD | 0.0% |
| 2018 | 5451.00 USD | -23.24% |
| 2017 | 7101.00 USD | -41.8% |
| 2016 | 12.2 Thousand USD | -92.96% |
| 2015 | 173.21 Thousand USD | 3.74% |
| 2014 | 166.95 Thousand USD | -52.24% |
| 2013 | 349.59 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 681.39 Thousand USD | 49.49% |
| 2024 Q2 | 549.28 Thousand USD | -19.39% |
| 2023 Q1 | 654.84 Thousand USD | -40.65% |
| 2023 FY | 1.83 Million USD | -58.63% |
| 2023 Q4 | 455.8 Thousand USD | -31.48% |
| 2023 Q3 | 665.18 Thousand USD | 986.06% |
| 2023 Q2 | 61.24 Thousand USD | -90.65% |
| 2022 FY | 4.43 Million USD | -11.24% |
| 2022 Q4 | 1.1 Million USD | 2.1% |
| 2022 Q3 | 1.08 Million USD | 12.17% |
| 2022 Q2 | 963.37 Thousand USD | -25.23% |
| 2022 Q1 | 1.28 Million USD | 37.95% |
| 2021 FY | 4.99 Million USD | 8.55% |
| 2021 Q4 | 933.97 Thousand USD | 7.81% |
| 2021 Q2 | 2.58 Million USD | 324.67% |
| 2021 Q1 | 609.34 Thousand USD | -86.64% |
| 2021 Q3 | 866.3 Thousand USD | -66.52% |
| 2020 Q2 | 18.97 Thousand USD | 19.68% |
| 2020 Q1 | 15.85 Thousand USD | 975.05% |
| 2020 FY | 4.6 Million USD | 84354.28% |
| 2020 Q4 | 4.56 Million USD | 60611.51% |
| 2020 Q3 | 7513.00 USD | -60.41% |
| 2019 Q4 | 1475.00 USD | 11.32% |
| 2019 FY | 5451.00 USD | 0.0% |
| 2019 Q3 | 1325.00 USD | 0.0% |
| 2019 Q2 | 1325.00 USD | 0.0% |
| 2019 Q1 | 1325.00 USD | 0.0% |
| 2018 FY | 5451.00 USD | -23.24% |
| 2017 FY | 7101.00 USD | -41.8% |
| 2016 FY | 12.2 Thousand USD | -92.96% |
| 2015 FY | 173.21 Thousand USD | 3.74% |
| 2014 FY | 166.95 Thousand USD | -52.24% |
| 2014 Q1 | 62.04 Thousand USD | -17.47% |
| 2013 Q1 | 97.36 Thousand USD | 0.0% |
| 2013 Q4 | 75.17 Thousand USD | 0.0% |
| 2013 FY | 349.59 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -37.416% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 63.604% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 93.79% |
| Nascent Biotech, Inc. | 2.22 Million USD | 17.704% |
| Rebus Holdings, Inc. | 664 Thousand USD | -176.37% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 95.074% |
| Qrons Inc. | 643.67 Thousand USD | -185.096% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -371.061% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 96.805% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -341.682% |
| Skye Bioscience, Inc. | 13.54 Million USD | 86.454% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 97.885% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 62.685% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -601.151% |
| SQZ Biotechnologies Company | 85.61 Million USD | 97.857% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 37.073% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -22.185% |
| Mesoblast Limited | 5.9 Million USD | 68.907% |
| Marizyme, Inc. | 19.23 Million USD | 90.462% |
| Genus plc | 147.7 Million USD | 98.758% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 79.097% |
| Pharming Group N.V. | 225.49 Million USD | 99.186% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 10.427% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -36.79% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 77.994% |
| ContraFect Corporation | 56.88 Million USD | 96.774% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 58.375% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -24.098% |
| IMV Inc. | 37.7 Million USD | 95.134% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 34.234% |
| MultiCell Technologies, Inc. | 567.42 USD | -323310.349% |
| ONE Bio Corp. | 6.44 Million USD | 71.522% |
| Accustem Sciences Inc. | 3.74 Million USD | 51.017% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 97.865% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -244.967% |
| Q BioMed Inc. | 3.43 Million USD | 46.602% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 92.575% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 30.159% |
| Biomind Labs Inc. | 994.18 Thousand USD | -84.583% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 98.153% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -4.286% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 72.684% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 1.57% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 7440.38% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 88.538% |
| GB Sciences, Inc. | 1.42 Million USD | -29.186% |
| Alpha Cognition Inc. | 9.7 Million USD | 81.092% |
| HST Global, Inc. | 140.9 Thousand USD | -1202.345% |
| CSL Limited | 3.44 Billion USD | 99.947% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -63.133% |
| Halberd Corporation | 74.84 Thousand USD | -2351.959% |
| Enzolytics Inc. | 2.17 Million USD | 15.802% |
| Agentix Corp. | 1.37 Million USD | -33.777% |
| Resverlogix Corp. | 12.71 Million USD | 85.564% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 49.733% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.88% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -75.775% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 23.695% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -16.193% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 46.106% |
| AVAX Technologies, Inc. | 7.31 Million USD | 74.897% |
| Zenith Capital Corp. | 8.94 Million USD | 79.48% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.778% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -10433.81% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 25.26% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -969.97% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 4.467% |
| Kadimastem Ltd | 2.41 Million USD | 23.859% |
| Helix BioMedix, Inc. | 1.97 Million USD | 6.944% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 83.113% |
| BioStem Technologies, Inc. | 22.97 Million USD | 92.013% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -911.155% |
| LadRx Corporation | 3.81 Million USD | 51.857% |
| Cell Source, Inc. | 4.32 Million USD | 57.573% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -98.709% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -98.709% |
| NovAccess Global Inc. | 2.46 Million USD | 25.607% |
| Affymax, Inc. | 39.38 Million USD | 95.341% |
| Itoco Inc. | 919.14 Thousand USD | -99.653% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 56.703% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -63.994% |
| Mobile Lads Corp. | 554.54 Thousand USD | -230.918% |
| CytoDyn Inc. | 18.05 Million USD | 89.838% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -7191.092% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -733.838% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -29.251% |
| SYBLEU INC | 160.87 Thousand USD | -1040.689% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -1.034% |
| International Stem Cell Corporation | 5.27 Million USD | 65.185% |
| Bioxytran, Inc. | 3.82 Million USD | 51.963% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -3385.99% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -8920.769% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 94.94% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -13.417% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -149.389% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 41.013% |
| Neutra Corp. | 243.82 Thousand USD | -652.64% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 89.488% |
| PureTech Health plc | 144.59 Million USD | 98.731% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 91.044% |
| IXICO plc | 4.7 Million USD | 61.013% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 79.14% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 98.442% |
| CSL Limited | 3.89 Billion USD | 99.953% |
| Cellectis S.A. | 97.32 Million USD | 98.114% |